Panel on Health Services

List of follow-up actions
(Position as at 16 April 2004)

Subject	Date of meeting	Follow-up action required	Administration's response
1. Reform of the Medical Council of Hong Kong	4 February 2002	The Administration agreed to give a response on whether it would set up a Complaints Office in the Department of Health (DH) to receive medical complaints, conduct preliminary investigation, make referrals and conduct mediation; and to examine at an appropriate time on gradually moving such Office towards independence.	Letters were issued on 26 April, 30 May, 26 June, 19 September, 29 October, 27 November, 23 December 2002, 30 January, 28 February, 3 and 30 April, 29 May, 25 June, 2 October, 3 and 29 November, 24 December 2003, 3 February, 2 March and 6 April 2004 to remind the Administration to provide a response. To this end, the Administration has repeatedly responded that it is working on the operational framework of the Complaints Office and will report to members in due course.
2. Rehabilitation of discharged mental patients	11 March 2002	The Administration agreed to provide a paper on rehabilitation services for discharged mental patients.	Letters were issued on 30 May, 26 June, 19 September, 29 October, 27 November, 23 December 2002, 30 January, 28 February, 3 and 30 April, 29 May, 25 June, 2 October and 3 and 29 November, 24 December 2003, 3 February, 2 March and 6 April 2004 to remind the Administration to provide a response. The Administration would provide a paper in due course.

Subject	Date of meeting	Follow-up action required	Administration's response
3. Working Group on Public/Private Interface - Progress Report	9 December 2002	The Administration undertook to provide statistics on the use of HA private services in the past year, including the number of patients who had used the private services and the types of services they used.	The Administration has advised that liaison with Hospital Authority (HA) is in progress on the requested information.
4. Redevelopment of Caritas Medical Centre, Phase 2	9 June 2003	The Administration undertook to provide information on established planning standards for public hospitals, and on the planning standards for public hospitals adopted in some developed economies.	The Administration is liaising with Hospital Authority on the requested information.
5. Tendering system for pharmaceutical products	9 July 2003	In a letter to the Panel dated 11 April 2003, the Administration undertook to amend Clause 4.1.2 of the tender document for drug procurement with a view to improving the clarity of the tender conditions concerning Marketing Authorisation.	The Administration's response in the **Appendix**.

Subject	Date of meeting	Follow-up action required	Administration's response
6. Continue discussion on the commitment for the fight against SARS	5 January 2004	The Administration was requested to provide information on the status of the some 100 doctors recruited during the last SARS outbreak and contract extension, namely, how many of them were still in the employ of HA, had left HA and would not be retained by HA after the expiry of their contract.	The Administration would report to the Panel by means of a letter in the near future.
7. 58MM - Construction of a new infectious disease centre attached to Princess Margaret Hospital	8 March 2004	The Administration was requested to provide a paper comparing the expertise and facilities for treating infectious disease patients amongst AHNH, PWH and NDH as well as reason(s) for selecting AHNH over PWH and NDH, for construction of a second infectious centre.	The Administration is reviewing whether the second infectious disease centre should be attached to AHNH and would report to the Panel in due course.

Council Business Division 2
Legislative Council Secretariat
16 April 2004

Appendix

BY FAX

中華人民共和國香港特別行政區政府總部衞生福利及食物局
Health, Welfare and Food Bureau
Government Secretariat, Government of the Hong Kong Special Administrative Region
The People's Republic of China

Our ref:
Your ref:

1 April 2004

Clerk to Panel on Health Services
Legislative Council
8 Jackson Road
Central, Hong Kong
(Attn: Ms Mary So)

Dear Ms So,

List of Follow-up Items
Tendering System for Pharmaceutical Products

We have indicated in our letter to the Panel dated 11 April 2003 that the Government and the Hospital Authority would review Clause 4.1.2 (ii) of the Conditions of Tender for the procurement of pharmaceutical products. We would like to report to the Panel that we have already amended the Clause in May 2003 to make it clear that, to satisfy the requirement provided therein, drug manufacturers in any country may produce marketing authorization from any member country of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, or from the People's Republic of China, Australia or Canada. The wording of the revised Clause 4.1.2 (ii) of the Conditions of Tender is reproduced in the Annex for Members' information.

Yours sincerely,

(Paul Cheng)
for Secretary for Health, Welfare and Food

香港中環花園道美利大廈閣樓及 19-21 樓 電話：(852) 2973 8284 傳真：(852) 2840 0467 2541 3352 2524 2743

附件
Annex

Conditions of Tender for Pharmaceutical Products

4. Tenderers are requested to submit copies of the following with the tender for consideration. Otherwise tenders may not be considered.

4.1.2 The Goods (i.e. the pharmaceutical products specified in Part V [Contract Schedule] of the tender :

(ii) For those Goods manufactured outside Hong Kong, a certified true copy of the Certificate of Drug/Product Registration of the Goods issued by the Pharmacy and Poisons Board of Hong Kong and a certified true copy of the Marketing Authorisation of the Goods issued by the national control authority of a member country of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use (ICH), or national control authority of the People's Republic of China (PRC), Australia or Canada.

Note 1: The following are currently ICH member countries – Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Luxembourg, Netherlands, Portugal, Spain, Sweden, UK and USA.

Note 2: Drug manufacturers in any country may produce Marketing Authorisation from any member countries of ICH, PRC, Australia or Canada in respect of the Goods.